Patents by Inventor Elena Kostik
Elena Kostik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190060473Abstract: The present invention provides Hsp90 drug conjugates (HDCs) comprising an Hsp90 ligand or prodrug thereof, a linker moiety and a payload moiety. The invention also provides methods for treating a disease or disorder in a subject, for example cancer, with an HDC.Type: ApplicationFiled: February 24, 2017Publication date: February 28, 2019Inventors: Dinesh U. Chimmanamada, Elena Kostik, Dharma Vutukuri, Weiwen Ying, Junyi Zhang
-
Patent number: 9090569Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.Type: GrantFiled: October 23, 2009Date of Patent: July 28, 2015Assignee: Synta Pharmaceuticals Corp.Inventors: Weiwen Ying, David James, Shijie Zhang, Teresa Przewloka, Junghyun Chae, Dinesh U. Chimmanamada, Chi-Wan Lee, Elena Kostik, Howard P. Ng, Kevin Foley, Zhenjian Du, James Barsoum
-
Patent number: 9051250Abstract: At least 70% by weight of Compound 1 is the single crystalline form, Form A, Form C, or Form D, of the compound. A pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent, and compound 1, wherein at least 70% by weight of the compound is the single crystalline form, Form A, Form C, or Form D, of the compound. A method of treating a subject with cancer comprises administering to the subject an effective amount of compound 1 or the pharmaceutical composition.Type: GrantFiled: January 27, 2014Date of Patent: June 9, 2015Assignee: Synta Pharmaceuticals Corp.Inventors: Elena Kostik, Lijun Sun, Joanna Dziewiszek, Jun Y. Choi
-
Patent number: 8901308Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.Type: GrantFiled: July 16, 2012Date of Patent: December 2, 2014Assignee: Synta Pharmaceuticals Corp.Inventors: Weiwen Ying, David James, Shijie Zhang, Teresa Przewloka, Junghyun Chae, Dinesh U. Chimmanamada, Chi-Wan Lee, Elena Kostik, Howard P. Ng, Kevin Foley, Zhenjian Du, James Barsoum
-
Publication number: 20140350115Abstract: At least 70% by weight of Compound 1 is the single crystalline form, Form A, Form C, or Form D, of the compound. A pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent, and compound 1, wherein at least 70% by weight of the compound is the single crystalline form, Form A, Form C, or Form D, of the compound. A method of treating a subject with cancer comprises administering to the subject an effective amount of compound 1 or the pharmaceutical composition.Type: ApplicationFiled: January 27, 2014Publication date: November 27, 2014Applicant: SYNTA PHARMACEUTICALS CORP.Inventors: Elena Kostik, Lijun Sun, Joanna Dziewiszek, Jun Y. Choi
-
Patent number: 8637704Abstract: At least 70% by weight of Compound 1 is the single crystalline form, Form A, Form C, or Form D, of the compound. A pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent, and compound 1, wherein at least 70% by weight of the compound is the single crystalline form, Form A, Form C, or Form D, of the compound. A method of treating a subject with cancer comprises administering to the subject an effective amount of compound 1 or the pharmaceutical composition.Type: GrantFiled: November 28, 2008Date of Patent: January 28, 2014Assignee: Synta Pharmaceuticals Corp.Inventors: Elena Kostik, Lijun Sun, Joanna Dziewiszek, Jun Y. Choi
-
Patent number: 8461208Abstract: Disclosed are bis(thio-hydrazide amide) disalts and pharmaceutical compositions thereof. Also disclosed are methods of using bis(thio-hydrazide amide) disalts to treat cancer.Type: GrantFiled: October 14, 2011Date of Patent: June 11, 2013Assignee: Synta Pharmaceuticals Corp.Inventors: Keizo Koya, Lijun Sun, Elena Kostik, Farid Vaghefi, Shoujun Chen, Noriaki Tatsuta, Guiqing Liang, Takayo Inoue, Zhi-Qiang Xia
-
Patent number: 8362055Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.Type: GrantFiled: June 14, 2010Date of Patent: January 29, 2013Assignee: Synta Pharmaceuticals, Inc.Inventors: Weiwen Ying, David James, Shijie Zhang, Teresa Przewloka, Junghyun Chae, Dinesh U. Chimmanamada, Chi-Wan Lee, Elena Kostik, Howard P. Ng, Kevin Foley, Zhenjian Du, James Barsoum
-
Publication number: 20120330009Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.Type: ApplicationFiled: July 16, 2012Publication date: December 27, 2012Inventors: Weiwen Ying, David James, Shijie Zhang, Teresa Przewloka, Junghyun Chae, Dinesh U. Chimmanamada, Chi-Wan Lee, Elena Kostik, Howard P. Ng, Kevin Foley, Zhenjian Du, James Barsoum
-
Patent number: 8236795Abstract: The invention relates to heterocyclic compounds, compositions including the compounds and methods of using and methods of making thereof. The compounds (and compositions) are useful, inter alia, in modulating IL-12 production and processes mediated by IL-12.Type: GrantFiled: March 24, 2010Date of Patent: August 7, 2012Assignee: Synta Pharmaceuticals Corp.Inventors: Lijun Sun, Elena Kostik, Teresa Przewloka, Howard P. Ng, Dinesh Chimmanamada, Zachary Demko
-
Publication number: 20120035266Abstract: Disclosed are bis(thio-hydrazide amide) disalts and pharmaceutical compositions thereof. Also disclosed are methods of using bis(thio-hydrazide amide) disalts to treat cancer.Type: ApplicationFiled: October 14, 2011Publication date: February 9, 2012Applicant: Synta Pharmaceuticals Corp.Inventors: Keizo KOYA, Lijun Sun, Elena Kostik, Farid Vaghefi, Shoujun Chen, Noriaki Tatsuta, Guiqing Liang, Takayo Inoue, Zhi-Qiang Xia
-
Patent number: 8048925Abstract: Disclosed are bis(thio-hydrazide amide) disalts, which are represented by Structural Formula (I): Y is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group. R1-R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. Z is —O or —S. M+ is a pharmaceutically acceptable monovalent cation and M2+ is a pharmaceutically acceptable divalent cation. Also, disclosed are pharmaceutical compositions comprising a bis(thio-hydrazide amide) disalt described above. Further disclosed are methods of treating a subject with cancer. The methods comprise the step of administering an effective amount of a bis(thio-hydrazide amide) disalt described above.Type: GrantFiled: August 30, 2010Date of Patent: November 1, 2011Assignee: Synta Pharmaceuticals Corp.Inventors: Keizo Koya, Lijun Sun, Elena Kostik, Farid Vaghefi, Shoujun Chen, Noriaki Tatsuta, Guiqing Liang, Takayo Inoue, Zhi-Qiang Xia
-
Publication number: 20110105749Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.Type: ApplicationFiled: June 14, 2010Publication date: May 5, 2011Inventors: Weiwen YING, David James, Shijie Zhang, Teresa Przewloka, Junghyun Chae, Dinesh U. Chimmanamada, Chi-Wan Lee, Elena Kostik, Howard P. Ng, Kevin Foley, Zhenjian Du, James Barsoum
-
Patent number: 7935698Abstract: This invention relates to compounds having a formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, prodrug or polymorph thereof wherein X is —C(Rg)?N-A. The invention also relates to methods of treating IL-12 overproduction-related disorders, methods of treating or preventing disorders related with excessive bone loss, methods for inhibiting osteoclast formation, and methods for treating or preventing a disorder associated with excessive bone resorption.Type: GrantFiled: November 10, 2004Date of Patent: May 3, 2011Assignee: Synta Pharmaceuticals CorporationInventors: Mitsunori Ono, Lijun Sun, Yumiko Wada, Elena Kostik, Howard P. Ng
-
Patent number: 7923557Abstract: Disclosed herein is a regioselective synthesis of compounds represented by formula (I): or a salt, solvate, clathrate, or prodrug thereof, wherein X, Y, R2, R3, R4, R7, R8, R9, R10, m and n are defined as within.Type: GrantFiled: November 10, 2005Date of Patent: April 12, 2011Assignee: Synta Pharmaceuticals CorporationInventors: Shijie Zhang, Elena Kostik, Lijun Sun
-
Patent number: 7919487Abstract: This invention relates to compounds of formula (I): their compositions and methods of use thereof. The compounds (and compositions) are useful in modulating IL-12 production and processes mediated by IL-12.Type: GrantFiled: November 10, 2005Date of Patent: April 5, 2011Assignee: Synta Pharmaceuticals CorporationInventors: Lijun Sun, Shijie Zhang, Keizo Koya, Dinesh Chimmanamada, Hao Li, David James, Elena Kostik
-
Publication number: 20110009397Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.Type: ApplicationFiled: October 23, 2009Publication date: January 13, 2011Inventors: Weiwen Ying, David James, Shijie Zhang, Teresa Przewloka, Junghyun Chae, Dinesh U. Chimmanamada, Chi-Wan Lee, Elena Kostik, Howard P. Ng, Kevin Foley, Zhenjian Du, James Barsoum
-
Publication number: 20100324143Abstract: Disclosed are bis(thio-hydrazide amide) disalts, which are represented by Structural Formula (I): Y is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group. R1-R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. Z is —O or —S. M+ is a pharmaceutically acceptable monovalent cation and M2+ is a pharmaceutically acceptable divalent cation. Also, disclosed are pharmaceutical compositions comprising a bis(thio-hydrazide amide) disalt described above. Further disclosed are methods of treating a subject with cancer. The methods comprise the step of administering an effective amount of a bis(thio-hydrazide amide) disalt described above.Type: ApplicationFiled: August 30, 2010Publication date: December 23, 2010Inventors: Keizo Koya, Lijun Sun, Elena Kostik, Farid Vaghefi, Shoujun Chen, Noriaki Tatsuta, Guiqing Liang, Takayo Inoue, Zhi-Qiang Xia
-
Patent number: 7825148Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.Type: GrantFiled: November 17, 2005Date of Patent: November 2, 2010Assignee: Synta Pharmaceuticals Corp.Inventors: Weiwen Ying, David James, Shijie Zhang, Teresa Przewloka, Junghyun Chae, Dinesh U. Chimmanamada, Chi-Wan Lee, Elena Kostik, Howard P. Ng, Kevin Foley, Zhenjian Du, James Barsoum
-
Publication number: 20100256132Abstract: The invention relates to heterocyclic compounds, compositions including the compounds and methods of using and methods of making thereof. The compounds (and compositions) are useful, inter alia, in modulating IL-12 production and processes mediated by IL-12.Type: ApplicationFiled: March 24, 2010Publication date: October 7, 2010Applicant: Synta Pharmaceuticals CorporationInventors: Lijun Sun, Elena Kostik, Teresa Przewloka, Howard P. Ng, Dinesh Chimmanamada, Zachary Demko